

## Prescribing Clinical Network

<b>Policy Statement</b>	Fast acting insulin aspart (Fiasp®) for the treatment of diabetes mellitus in adult patients
<b>Policy No:</b>	PCN 271 -2017
<b>Date of Issue</b>	August -2017
<b>Review Date:</b>	August -2020 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<b>Recommendations:</b> <p>The Prescribing Clinical Network recommends the use of Fiasp® (Fast acting insulin aspart) for adult patients (over 18 years of age) in type I &amp; type II diabetes.</p> <p>Fiasp® should be initiated by diabetologists only, in patients not at target on current treatment regimens.</p> <p>Fiasp® (Fast acting insulin aspart) will be considered as BLUE (with no information sheet) on the traffic light system with minimum prescribing duration of three months by secondary care before transferring to primary care</p>	
<b>Key Considerations:</b> <ul style="list-style-type: none"> <li>• Consideration of the trial design and evidence from published trials ONSET 1 &amp; 2.</li> <li>• <a href="http://www.medicines.org.uk">www.medicines.org.uk</a> 'black triangle' status.</li> <li>• Scottish Medicines Consortium (<a href="http://www.scottishmedicines.org.uk">www.scottishmedicines.org.uk</a>) positive recommendation in April 2017 &amp; All Wales Medicines Strategy Group (AWMSG) (<a href="http://www.wales.nhs.uk">www.wales.nhs.uk</a>) positive recommendation in November 2016</li> <li>• Fiasp is cost comparable to Novorapid.</li> </ul>	
<b>Date taken to Prescribing Clinical Network</b>	2 <sup>nd</sup> August 2017
<b>Agreed by PCN members</b>	14 <sup>th</sup> August 2017

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG